• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于免疫反应通路调控探索的肾透明细胞癌预后风险特征识别

Identification of a Prognostic Risk Signature of Kidney Renal Clear Cell Carcinoma Based on Regulating the Immune Response Pathway Exploration.

作者信息

Wu Guangzhen, Xu Yingkun, Han Chenglin, Wang Zilong, Li Jiayi, Wang Qifei, Che Xiangyu

机构信息

Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.

Department of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

出版信息

J Oncol. 2020 Dec 30;2020:6657013. doi: 10.1155/2020/6657013. eCollection 2020.

DOI:10.1155/2020/6657013
PMID:33456463
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7787716/
Abstract

PURPOSE

To construct a survival model for predicting the prognosis of patients with kidney renal clear cell carcinoma (KIRC) based on gene expression related to immune response regulation.

MATERIALS AND METHODS

KIRC mRNA sequencing data and patient clinical data were downloaded from the TCGA database. The pathways and genes involved in the regulation of the immune response were identified from the GSEA database. A single factor Cox analysis was used to determine the association of mRNA in relation to patient prognosis ( < 0.05). The prognostic risk model was further established using the LASSO regression curve. The survival prognosis model was constructed, and the sensitivity and specificity of the model were evaluated using the ROC curve.

RESULTS

Compared with normal kidney tissues, there were 28 dysregulated mRNA expressions in KIRC tissues ( < 0.05). Univariate Cox regression analysis revealed that 12 mRNAs were related to the prognosis of patients with renal cell carcinoma. The LASSO regression curve drew a risk signature consisting of six genes: TRAF6, FYN, IKBKG, LAT2, C2, IL4, EREG, TRAF2, and IL12A. The five-year ROC area analysis (AUC) showed that the model has good sensitivity and specificity (AUC >0.712).

CONCLUSION

We constructed a risk prediction model based on the regulated immune response-related genes, which can effectively predict the survival of patients with KIRC.

摘要

目的

基于与免疫反应调节相关的基因表达构建一个预测肾透明细胞癌(KIRC)患者预后的生存模型。

材料与方法

从TCGA数据库下载KIRC mRNA测序数据和患者临床数据。从GSEA数据库中识别参与免疫反应调节的通路和基因。采用单因素Cox分析确定mRNA与患者预后的相关性(<0.05)。使用LASSO回归曲线进一步建立预后风险模型。构建生存预后模型,并使用ROC曲线评估模型的敏感性和特异性。

结果

与正常肾组织相比,KIRC组织中有28种mRNA表达失调(<0.05)。单因素Cox回归分析显示,12种mRNA与肾细胞癌患者的预后相关。LASSO回归曲线得出了一个由六个基因组成的风险特征:TRAF6、FYN、IKBKG、LAT2、C2、IL4、EREG、TRAF2和IL12A。五年ROC面积分析(AUC)表明该模型具有良好的敏感性和特异性(AUC>0.712)。

结论

我们基于免疫反应调节相关基因构建了一个风险预测模型,该模型可以有效预测KIRC患者的生存情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0451/7787716/c646bcc22297/JO2020-6657013.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0451/7787716/664fbf460d0a/JO2020-6657013.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0451/7787716/16b917eabdd5/JO2020-6657013.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0451/7787716/34fd67870571/JO2020-6657013.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0451/7787716/c646bcc22297/JO2020-6657013.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0451/7787716/664fbf460d0a/JO2020-6657013.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0451/7787716/16b917eabdd5/JO2020-6657013.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0451/7787716/34fd67870571/JO2020-6657013.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0451/7787716/c646bcc22297/JO2020-6657013.004.jpg

相似文献

1
Identification of a Prognostic Risk Signature of Kidney Renal Clear Cell Carcinoma Based on Regulating the Immune Response Pathway Exploration.基于免疫反应通路调控探索的肾透明细胞癌预后风险特征识别
J Oncol. 2020 Dec 30;2020:6657013. doi: 10.1155/2020/6657013. eCollection 2020.
2
Construction and validation of an autophagy-related long noncoding RNA signature for prognosis prediction in kidney renal clear cell carcinoma patients.构建并验证自噬相关长非编码 RNA 标志物用于预测肾透明细胞癌患者的预后
Cancer Med. 2021 Apr;10(7):2359-2369. doi: 10.1002/cam4.3820. Epub 2021 Mar 2.
3
Establishment of a new prognostic risk model of MAPK pathway-related molecules in kidney renal clear cell carcinoma based on genomes and transcriptomes analysis.基于基因组和转录组分析建立肾透明细胞癌中MAPK信号通路相关分子的新预后风险模型
Front Oncol. 2023 Mar 10;13:1077309. doi: 10.3389/fonc.2023.1077309. eCollection 2023.
4
A Novel Prognostic Signature Associated With the Tumor Microenvironment in Kidney Renal Clear Cell Carcinoma.一种与肾透明细胞癌肿瘤微环境相关的新型预后标志物
Front Oncol. 2022 Jul 4;12:912155. doi: 10.3389/fonc.2022.912155. eCollection 2022.
5
Identification and Validation of a Necroptosis-Related Prognostic Signature for Kidney Renal Clear Cell Carcinoma.肾透明细胞癌坏死性凋亡相关预后标志物的鉴定与验证
Stem Cells Int. 2023 Mar 3;2023:8446765. doi: 10.1155/2023/8446765. eCollection 2023.
6
Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.系统分析剪接变异特征揭示了肾透明细胞癌的预后预测因子。
J Cell Physiol. 2019 Dec;234(12):22753-22764. doi: 10.1002/jcp.28840. Epub 2019 May 29.
7
miRNA-21 and miRNA-223 expression signature as a predictor for lymph node metastasis, distant metastasis and survival in kidney renal clear cell carcinoma.miRNA-21和miRNA-223表达特征作为肾透明细胞癌淋巴结转移、远处转移及生存的预测指标
J Cancer. 2018 Sep 8;9(20):3651-3659. doi: 10.7150/jca.27117. eCollection 2018.
8
The Role of ERBB Signaling Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma and Establishing a Prognostic Risk Assessment Model for Patients.ERBB信号通路相关基因在肾透明细胞癌中的作用及建立患者预后风险评估模型
Front Genet. 2022 Jul 12;13:862210. doi: 10.3389/fgene.2022.862210. eCollection 2022.
9
Development and Validation of Nine-RNA Binding Protein Signature Predicting Overall Survival for Kidney Renal Clear Cell Carcinoma.预测肾透明细胞癌总生存期的九种RNA结合蛋白特征的开发与验证
Front Genet. 2020 Oct 2;11:568192. doi: 10.3389/fgene.2020.568192. eCollection 2020.
10
Identification of small molecule drugs and development of a novel autophagy-related prognostic signature for kidney renal clear cell carcinoma.鉴定小分子药物并开发用于肾透明细胞癌的新型自噬相关预后标志物。
Cancer Med. 2020 Oct;9(19):7034-7051. doi: 10.1002/cam4.3367. Epub 2020 Aug 11.

引用本文的文献

1
Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast Cancer.开发和验证一种新的 PPAR 信号通路相关预测模型,以预测乳腺癌的预后。
J Immunol Res. 2022 Jun 2;2022:9412119. doi: 10.1155/2022/9412119. eCollection 2022.
2
Construction and Validation of Angiogenesis-Related Prognostic Risk Signature to Facilitate Survival Prediction and Biomarker Excavation of Breast Cancer Patients.构建和验证血管生成相关的预后风险特征以促进乳腺癌患者的生存预测和生物标志物挖掘
J Oncol. 2022 Apr 20;2022:1525245. doi: 10.1155/2022/1525245. eCollection 2022.

本文引用的文献

1
A New Prognostic Risk Model Based on PPAR Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma.一种基于PPAR通路相关基因的肾透明细胞癌新预后风险模型
PPAR Res. 2020 Sep 22;2020:6937475. doi: 10.1155/2020/6937475. eCollection 2020.
2
High Expression of Interleukin-12A and Its Association with the Clinicopathology and Prognosis of Differentiated Thyroid Cancer.白细胞介素-12A的高表达及其与分化型甲状腺癌临床病理和预后的关系
Eur Thyroid J. 2020 May;9(3):139-147. doi: 10.1159/000505811. Epub 2020 Apr 17.
3
Obesity induces limited changes to systemic and local immune profiles in treatment-naive human clear cell renal cell carcinoma.
肥胖症在未经治疗的人类透明细胞肾细胞癌中引起全身性和局部免疫谱的有限变化。
PLoS One. 2020 May 29;15(5):e0233795. doi: 10.1371/journal.pone.0233795. eCollection 2020.
4
TIMER2.0 for analysis of tumor-infiltrating immune cells.TIMER2.0 用于分析肿瘤浸润免疫细胞。
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514. doi: 10.1093/nar/gkaa407.
5
Suppression of complement component 2 expression by hepatitis B virus contributes to the viral persistence in chronic hepatitis B patients.乙型肝炎病毒抑制补体成分 2 的表达有助于慢性乙型肝炎患者的病毒持续存在。
J Viral Hepat. 2020 Oct;27(10):1071-1081. doi: 10.1111/jvh.13319. Epub 2020 May 26.
6
Screening and Identification of Key Biomarkers for Bladder Cancer: A Study Based on TCGA and GEO Data.基于 TCGA 和 GEO 数据的膀胱癌关键生物标志物的筛选和鉴定:一项研究。
Biomed Res Int. 2020 Jan 23;2020:8283401. doi: 10.1155/2020/8283401. eCollection 2020.
7
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
8
Traf6 inhibitor boosts antitumor immunity by impeding regulatory T cell migration in Hepa1-6 tumor model.Traf6 抑制剂通过阻碍 Hepa1-6 肿瘤模型中调节性 T 细胞的迁移来增强抗肿瘤免疫。
Int Immunopharmacol. 2019 Dec;77:105965. doi: 10.1016/j.intimp.2019.105965. Epub 2019 Oct 26.
9
TRAF6 inhibits colorectal cancer metastasis through regulating selective autophagic CTNNB1/β-catenin degradation and is targeted for GSK3B/GSK3β-mediated phosphorylation and degradation.TRAF6 通过调节选择性自噬 CTNNB1/β-连环蛋白降解来抑制结直肠癌转移,并且其可被 GSK3B/GSK3β 介导的磷酸化和降解所靶向。
Autophagy. 2019 Sep;15(9):1506-1522. doi: 10.1080/15548627.2019.1586250. Epub 2019 Mar 4.
10
Role of miRNAs in immune responses and immunotherapy in cancer.miRNAs 在癌症免疫反应和免疫治疗中的作用。
Genes Chromosomes Cancer. 2019 Apr;58(4):244-253. doi: 10.1002/gcc.22725.